Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ORGANIZATION
ORGANIZATION
- Daratumumab Affects Transfusion Tests, Scientific Societies Warn
December 13, 2016
- Ongoing Discussions without Chuikyo Deplorable: JPWA Head
December 12, 2016
- Annual Price Revisions Will Demotivate Pharmas, Foreign HQs Harboring Serious Concerns: PhRMA Japan Chief
December 9, 2016
- Drug Pricing Policy Can’t Be Defined in 2-3 Weeks: PhRMA Exec
December 6, 2016
- JPWA Shows Firm Opposition to Annual Revisions
December 5, 2016
- Annual Price Revisions of All Drugs Unacceptable: JMA Chief
December 1, 2016
- Japan, US, Europe Trade Groups Vehemently Oppose Annual Price Revisions
December 1, 2016
- JGA Rebuts Govt Panel Members’ Pricing Reform Proposals in Emergency Statement
November 30, 2016
- Drug Pricing Rules Should Be Fundamentally Reviewed: JMA Chief
November 28, 2016
- EFPIA, PhRMA “Regret” Out-of-Cycle Price Slash for Opdivo
November 22, 2016
- EFPIA Japan Lauds MHLW Task Force’s Proposal on Blood Products and Vaccines Industries
November 22, 2016
- JPMA to Straighten Up Industry Positions on FY2018 Pricing Reform
November 18, 2016
- Opdivo Price Cut “Unavoidable” to Maintain Universal Healthcare: JMA Chief
November 18, 2016
- FPMAJ, JPMA Issue Joint Statement on Emergency Price Cut for Opdivo
November 17, 2016
- Drug Costs Is Main Culprit of Ballooning Medical Spending: Hodanren
November 16, 2016
- Japan Society of Generic Medicines Calls for Lawmaker-Sponsored Bill to Push Biosimilar Use
November 14, 2016
- PhRMA, EFPIA Members Conducted 825 Japan Clinical Trials in 2015
November 8, 2016
- Japan Biosimilar Association Draws Gradual Rise in Membership, Mixed Interests
November 7, 2016
- Realtor-Led Tokyo Life Sciences Hub Initiative Aims to Fill Void between Academia, Pharmas
October 27, 2016
- Japan Should Adopt French-Type HTA: JMA Exec Suzuki
October 26, 2016
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…